Literature DB >> 29784453

Executive summary of outpatient parenteral antimicrobial therapy: Guidelines of the Spanish Society of Clinical Microbiology and Infectious Diseases and the Spanish Domiciliary Hospitalisation Society.

Luis Eduardo López Cortés1, Abel Mujal Martínez2, Magdalena Fernández Martínez de Mandojana3, Natalia Martín4, Mercè Gil Bermejo5, Joan Solà Aznar6, Eulalia Villegas Bruguera7, Maria José Peláez Cantero8, Pilar Retamar Gentil9, Miriam Delgado Vicente10, Víctor José González-Ramallo11, Miguel Ángel Ponce González12, Manuel Mirón Rubio13, M Montserrat Gómez Rodríguez de Mendarozqueta10, Miguel Ángel Goenaga Sánchez14, Pedro Sanroma Mendizábal15, Elena Delgado Mejía16, Marcos Pajarón Guerrero15.   

Abstract

Outpatient parenteral antimicrobial therapy (OPAT) programmes make it possible to start or complete intravenous antimicrobial therapy for practically any type of infection at home, provided that patient selection is appropriate for the type of OPAT programme available. Although the clinical management of infections in the home setting is comparable in many respects to that offered in conventional hospitalization (selection of antibiotics, duration of treatment, etc.), there are many aspects that are specific to this care modality. It is essential to be aware of them so that OPAT continues to be as safe and effective as inpatient care. The objective of this clinical guideline is therefore to provide evidence- and expert-based recommendations with a view to standardizing clinical practice in this care modality and contribute to a progressive increase in the number of patients who can be cared for and receive intravenous therapy in their own homes.
Copyright © 2018 Elsevier España, S.L.U. and Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica. All rights reserved.

Entities:  

Keywords:  Casa; Home; Intravenous therapy; Outpatient parenteral antimicrobial therapy; Tratamiento antibiótico domiciliario endovenoso; Tratamiento endovenoso

Mesh:

Substances:

Year:  2018        PMID: 29784453     DOI: 10.1016/j.eimc.2018.03.012

Source DB:  PubMed          Journal:  Enferm Infecc Microbiol Clin (Engl Ed)        ISSN: 2529-993X


  6 in total

Review 1.  Treatment of infections caused by multi-resistant microorganisms in hospital at home units.

Authors:  M Mirón-Rubio
Journal:  Rev Esp Quimioter       Date:  2021-09-30       Impact factor: 1.553

2.  Ampicillin and Ceftriaxone Solution Stability at Different Temperatures in Outpatient Parenteral Antimicrobial Therapy.

Authors:  L Herrera-Hidalgo; L E López-Cortes; R Luque-Márquez; J Gálvez-Acebal; A de Alarcón; L F López-Cortes; A Gutiérrez-Valencia; M V Gil-Navarro
Journal:  Antimicrob Agents Chemother       Date:  2020-06-23       Impact factor: 5.191

Review 3.  Successful Integration of Clinical Pharmacists in an OPAT Program: A Real-Life Multidisciplinary Circuit.

Authors:  Sara Ortonobes; Abel Mujal-Martínez; María de Castro Julve; Alba González-Sánchez; Rafael Jiménez-Pérez; Manuel Hernández-Ávila; Natalia De Alfonso; Ingrid Maye-Pérez; Teresa Valle-Delmás; Alba Rodríguez-Sánchez; Jessica Pino-García; Mònica Gómez-Valent
Journal:  Antibiotics (Basel)       Date:  2022-08-19

4.  [Integral approach to the acute exacerbation of chronic obstructive pulmonary disease].

Authors:  J González Del Castillo; F J Candel; J de la Fuente; F Gordo; F J Martín-Sánchez; R Menéndez; A Mujal; J Barberán
Journal:  Rev Esp Quimioter       Date:  2018-10-04       Impact factor: 1.553

Review 5.  Enterococcus faecalis Endocarditis and Outpatient Treatment: A Systematic Review of Current Alternatives.

Authors:  Laura Herrera-Hidalgo; Arístides de Alarcón; Luis E López-Cortes; Rafael Luque-Márquez; Luis F López-Cortes; Alicia Gutiérrez-Valencia; María V Gil-Navarro
Journal:  Antibiotics (Basel)       Date:  2020-09-30

6.  Clinical Outcomes of an Innovative Cefazolin Delivery Program for MSSA Infections in OPAT.

Authors:  Laura Herrera-Hidalgo; Rafael Luque-Márquez; Aristides de Alarcon; Ana Belén Guisado-Gil; Belen Gutierrez-Gutierrez; Maria Dolores Navarro-Amuedo; Julia Praena-Segovia; Juan Manuel Carmona-Caballero; Elena Fraile-Ramos; Alicia Gutierrez-Valencia; Luis Eduardo Lopez-Cortes; Maria Victoria Gil-Navarro
Journal:  J Clin Med       Date:  2022-03-11       Impact factor: 4.241

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.